Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
2026年8月7日 更新者:Rigel Pharmaceuticals
A Multi-center, Open-label, Drug-drug Interaction Study to Evaluate the Effect of Pralsetinib (Gavreto) on the Pharmacokinetics of CYP3A4, CYP2C8, and CYP2C9 Substrates, and Hormones Estradiol/Norethisterone Acetate in Patients With Advanced or Metastatic Solid Tumors
An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with rearranged during transfection (RET) fusion- or mutation-positive solid tumors
調査の概要
状態
募集
研究の種類
介入
入学 (推定)
12
段階
- フェーズ 4
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前:Kay Patel
- 電話番号:(650) 624-1100
- メール:kpatel@rigel.com
研究場所
-
-
-
Madrid、スペイン、28050
- 募集
- Hospital Universitario HM Sanchinarro
-
コンタクト:
- Irene Moreno, MD
- メール:irene.moreno@startmadrid.com
-
-
La Rioja
-
Logroño、La Rioja、スペイン、26006
- 募集
- Hospital Universitario San Pedro
-
コンタクト:
- Maria De Miguel, MD, PhD, MBA
- メール:maria.demiguel@startrioja.com
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Must be willing and able to participate and comply with all study requirements and to provide signed and dated written informed consent
- Adult male or female ≥ 18 years of age at the time of signing the informed consent form.
- Must have a body mass index (BMI) ≥ 18 and ≤ 32 kg/m² and a minimum body weight of 50 kg at screening.
- Must have an Eastern Cooperative Oncology Group performance status ≤ 2.
- Must have recovered from the non-hematologic toxic effects of prior treatment to Grade ≤ 1, or baseline value (excluding infertility, alopecia, or Grade 1 neuropathy)
- Must have a confirmed diagnosis of advanced or metastatic solid tumor that has relapsed after, or is not responsive to, standard therapies and harbors an oncogenic RET fusion or mutation as determined by a validated test.
Must have adequate organ function, defined by the following:
- Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹/L.
- Platelet count ≥ 75 × 10⁹/L.
- Hemoglobin ≥ 9 g/dL.
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN), or ≤ 5 × ULN in patients with known liver metastases.
- Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN in patients with Gilbert syndrome).
- Creatinine clearance ≥ 40 mL/min using the Cockcroft-Gault equation.
- Serum phosphorus ≤ 5.5 mg/dL.
- International normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (aPTT) within normal laboratory limits.
- Must be at least 4 weeks from major surgery, radiotherapy, chemotherapy, immunotherapy, kinase/targeted therapy, or gene therapy prior to the first dose of study treatment and recovered from treatment-related toxicities to ≤ Grade 1 (excluding alopecia). Must be ≥ 6 weeks since last treatment if they received a long-acting agent such as a nitrosourea, mitomycin, or monoclonal antibodies. In general, a treatment interval of two half-lives should be considered and discussed with the Sponsor. (Concurrent cancer therapy of any type is not permitted).
- Female patients may participate if they are not of childbearing potential (e.g., surgically sterile or postmenopausal).
- Male patients with female partners of childbearing potential must agree to use highly effective contraception during study treatment and for 90 days after the last dose of study treatment.
- Male patients must refrain from sperm donation during study treatment and for 90 days after the last dose of study treatment.
Exclusion Criteria:
- Clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, electrocardiogram (ECG), or laboratory tests at screening that, in the investigator's judgment, are likely to interfere with the objectives of the trial or the safety of the patient.
- Surgery (e.g., gastric bypass) or medical condition that may significantly affect absorption of study medications, as judged by the investigator.
- History of pneumonitis within the last 12 months.
- History of active or latent tuberculosis (TB), regardless of treatment history, or a positive screening test for latent Mycobacterium tuberculosis infection by QuantiFERON® TB Gold. Indeterminate results may be confirmed by repeat testing or by a purified protein derivative (PPD) skin test.
- Serious infection requiring intravenous or systemic antibiotics within 7 days prior to initiation of study treatment, or any active infection that, in the opinion of the investigator, could impact patient safety (e.g., COVID-19 or influenza).
Clinically significant, uncontrolled cardiovascular disease, including:
- New York Heart Association (NYHA) Class III or IV congestive heart failure.
- Myocardial infarction or unstable angina within the previous 6 months, clinically significant uncontrolled arrhythmias, including bradyarrhythmias that may cause QT prolongation (e.g., second- or third-degree heart block).
- Uncontrolled hypertension (i.e., mean systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg on 3 repeated measurements) or clinically significant hypotension (i.e., systolic blood pressure <90 mmHg and/or diastolic blood pressure <50 mmHg) or severe episodes of orthostatic hypotension.
- History of prolonged QT syndrome or torsades de pointes, or familial history of long QT syndrome.
- QTcF ≥470 ms on at least 2 ECGs performed >30 minutes apart.
- Central nervous system (CNS) metastases or primary CNS tumor.
- Use of systemic corticosteroids within 4 weeks prior to first dose of study treatment.
- More than 30 Gy of radiotherapy to the lung within 6 months prior to check-in.
- History of multiple and/or severe allergies to drugs or foods, or history of severe anaphylactic reaction.
- Use of prohibited medications or procedures
- Medical conditions, treatments, or underlying diseases that constitute contraindications to the use of study substrates or probe drugs
- Ingestion of alcohol within 72 hours prior to first study drug administration and during the study period.
- Participation in another investigational drug trial within 30 days prior to study drug administration (or within 5 half-lives of the investigational drug, whichever is longer) or exposure to more than 3 investigational agents within 12 months prior to study drug administration.
- Positive serology for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody at screening (a negative PCR test overrides a positive serology).
- Positive human immunodeficiency virus (HIV) test at screening.
- Positive urine drug screen (unless attributable to concomitant medication) or positive alcohol breath test at screening and/or Day -1.
- Patients who are legally incapacitated, have limited legal capacity, or are otherwise considered vulnerable.
- Female patients who are pregnant or breastfeeding.
- Patients who plan to become pregnant or father a child (including ova or sperm donation) during the study or within 3 months after the last dose of study drug.
- Known allergy or history of hypersensitivity to study drug(s) or their excipients.
- Concomitant use of strong or moderate CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and/or CYP3A4 inhibitors within 7 days or 5 half-lives (whichever is longer) prior to first dose of study treatment.
- Concomitant use of strong or moderate CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and/or CYP3A4 inducers within 14 days or 5 half-lives (whichever is longer) prior to first dose of study treatment.
- History of or active clinically significant cardiovascular, respiratory, gastrointestinal, renal, hepatic, neurological, psychiatric, musculoskeletal, genitourinary, dermatologic, hematologic, or other disorder that, in the investigator's judgment, could interfere with study participation or the absorption, metabolism, or excretion of study treatment.
- History of prior second malignancy unless disease-free for ≥ 12 months or considered surgically cured. Patients with nonmelanoma skin cancers or with carcinomas in situ at any time following curative intent surgery and low grade, early-stage prostate cancer (Gleason score 6 or below, stage 1 or 2) with no requirement for therapy at any time prior to the study, or previously resected are also eligible.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Pralsetinib with CYP450 Probe Substrates and Hormonal Contraceptive
|
Pralsetinib 400mg orally (PO) once daily (QD) from Day 4 to Day 10, with an option to continue up to Day 33
Midazolam, repaglinide, and losartan (CYP probe substrates) and, for female participants, estradiol/norethisterone acetate (hormonal probe substrate), administered orally (PO) once on Day 1 and once on Day 9.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Area Under the Plasma Concentration-Time Curve from zero to infinity (AUC0-inf)
時間枠:Up to 48 hours post-dose or as appropriate for each probe substrate
|
To evaluate the effect of pralsetinib on the overall exposure of CYP3A4, CYP2C8, and CYP2C9, probe substrates, and hormonal contraceptive by measuring AUC0-inf for each probe substrate and its relevant metabolites.
|
Up to 48 hours post-dose or as appropriate for each probe substrate
|
|
Area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUClast)
時間枠:Up to 48 hours after each probe drug administration
|
To evaluate the effect of pralsetinib on the overall exposure of CYP3A4, CYP2C8, and CYP2C9 probe substrates, and hormonal contraceptive by measuring AUClast for each probe substrate and its relevant metabolites.
|
Up to 48 hours after each probe drug administration
|
|
Maximum Peak Plasma Concentration (Cmax)
時間枠:Up to 48 hours after each probe drug administration
|
To evaluate how pralsetinib affects the peak levels of probe substrates, and hormonal contraceptive, in the blood after they are taken alone and again after treatment with pralsetinib
|
Up to 48 hours after each probe drug administration
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to Maximum Plasma Concentration (tmax)
時間枠:Up to 48 hours after each probe drug administration
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to assess how pralsetinib affects the time required to reach peak plasma concentration for each probe drug.
|
Up to 48 hours after each probe drug administration
|
|
Terminal Half-Life (t½)
時間枠:Up to 48 hours after each probe drug administration
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization To evaluate the effect of pralsetinib on the terminal half-life of each probe drug
|
Up to 48 hours after each probe drug administration
|
|
Percent of Area Under the plasma concentration-time curve obtained at extrapolation (%AUCex)
時間枠:Up to 48 hours after each probe drug administration
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to determine the proportion of the AUC that is extrapolated, providing insight into pralsetinib's effect on drug elimination
|
Up to 48 hours after each probe drug administration
|
|
Mean residence time (MRT)
時間枠:Up to 48 hours after each probe drug administration
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to assess how pralsetinib affects the average time each probe drug remains in the body
|
Up to 48 hours after each probe drug administration
|
|
Terminal Elimination Rate Constant (λz)
時間枠:Up to 48 hours after each probe drug administration
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to assess how pralsetinib affects the terminal elimination rate constant of each probe drug
|
Up to 48 hours after each probe drug administration
|
|
Apparent Total Body Clearance (CL/F)
時間枠:Up to 48 hours after each probe drug administration
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to evaluate the effect of pralsetinib on the apparent total body clearance of each probe drug
|
Up to 48 hours after each probe drug administration
|
|
Apparent Volume of Distribution (Vz/F)
時間枠:Up to 48 hours after each probe drug administration
|
Venous whole blood samples will be collected for activity-based pharmacokinetics characterization to assess how pralsetinib influences the apparent volume of distribution of each probe drug
|
Up to 48 hours after each probe drug administration
|
|
Safety and Tolerability
時間枠:From the start of treatment through approximately 30 days after the last dose of study treatment
|
Incidence, frequency, relatedness, and severity of treatment-emergent adverse events (TEAEs) associated with co-administration of pralsetinib and probe substrates
|
From the start of treatment through approximately 30 days after the last dose of study treatment
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
スポンサー
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2026年3月4日
一次修了 (推定)
2027年7月30日
研究の完了 (推定)
2027年8月30日
試験登録日
最初に提出
2026年7月9日
QC基準を満たした最初の提出物
2026年7月9日
最初の投稿 (実際)
2026年7月15日
学習記録の更新
投稿された最後の更新 (実際)
2026年8月10日
QC基準を満たした最後の更新が送信されました
2026年8月7日
最終確認日
2026年8月1日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 内分泌系疾患
- 部位別新生物
- 気道疾患
- 肺疾患
- 内分泌腺腫瘍
- 頭頸部腫瘍
- 気道腫瘍
- 胸部腫瘍
- 肺新生物
- がん、気管支原性
- 気管支腫瘍
- 甲状腺疾患
- 新生物
- がん、非小細胞肺
- 甲状腺腫瘍
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 酵素
- 酵素と補酵素
- 酸化還元酵素
- シトクロム
- 混合機能オキシゲナーゼ
- オキシゲナーゼ
- ヘメプロテン
- アリール炭化水素水酸化酵素
- シトクロムP-450酵素系
- シトクロムP450ファミリー2
- CH-NH基ドナーに作用するオキシドレダクターゼ
- シトクロムP450ファミリー3
- N-脱メチル化酸化還元酵素
- プラルセチニブ
- チトクロームP-450 CYP2C8
- シトクロムP-450 CYP3A
その他の研究ID番号
- RGL-RET-001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
はい
米国FDA規制機器製品の研究
いいえ
米国で製造され、米国から輸出された製品。
はい
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。